NewAmsterdam Pharma (NAMS) Return on Sales (2023 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Return on Sales for 3 consecutive years, with 2341.34% as the latest value for Q4 2025.
- Quarterly Return on Sales fell 233413.0% to 2341.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.06% through Dec 2025, down 375.0% year-over-year, with the annual reading at 9.06% for FY2025, 375.0% down from the prior year.
- Return on Sales hit 2341.34% in Q4 2025 for NewAmsterdam Pharma, down from 206.91% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.57% in Q3 2024 to a low of 2341.34% in Q4 2025.
- Historically, Return on Sales has averaged 229.92% across 3 years, with a median of 16.57% in 2024.
- Biggest five-year swings in Return on Sales: surged 5439bps in 2024 and later plummeted -233413bps in 2025.
- Year by year, Return on Sales stood at 61.6% in 2023, then skyrocketed by 88bps to 7.22% in 2024, then crashed by -32342bps to 2341.34% in 2025.
- Business Quant data shows Return on Sales for NAMS at 2341.34% in Q4 2025, 206.91% in Q3 2025, and 0.91% in Q2 2025.